Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514820 | 1.00 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| Iodomethane SCHEMBL9116697 | 0.95 | CA1 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17008160 | 0.84 | CYP1A1 (0.53) | POLBTSHRSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL943297 | 0.82 | CA1 (0.60) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4644640 | 0.82 | CA1 (0.60) | CA1CA2CA7CA9CA12 | |
| SCHEMBL31345525 | 0.82 | CA1 (0.60) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2774997 | 0.82 | SLC6A2 (0.49) | CA1CA2CA7CA9CA12 | |
| SCHEMBL28061634 | 0.81 | CA1 (0.52) | CA1CA2CA7CA9CA12 | |
| Lithium SCHEMBL9505754 | 0.80 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL25820737 | 0.80 | POLB (0.42) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371674-A | Preparation method of donor-acceptor type metal organic framework photocatalyst and application of photocatalytic amine oxide/thioether | 长沙理工大学 | 2025-01-28 | — | — | CN | claimed |
| CN-111320560-B | Method for preparing sulfoxide compound by photocatalytic oxidation of thioether in aqueous phase | 南阳师范学院 | 2022-06-24 | — | — | CN | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| JP-60092233-A | — | — | None | — | — | JP | disclosed |
| JP-60092231-A | — | — | None | — | — | JP | disclosed |
| US-20250331405-A1 | DISPLAY DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-10-23 | — | — | US | disclosed |
| WO-2025073057-A1 | METHODS FOR PREPARING SULFILIMINES AND SULFOXIMINES FROM THIOETHERS USING O-(DIPHENYLPHOSPHINYL)HYDROXYL AMINE (DPPH), AND AMATOXIN ANALOGS PREPARED FROM SUCH METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-04-10 | — | — | WO | disclosed |
| EP-4534528-A1 | NOVEL SULFANONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2025-04-09 | — | — | EP | disclosed |
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-10 | — | — | US | disclosed |
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-0191496-A2 | Triazine Derivatives, a process for preparing the derivatives, and herbicides containing the derivatives as the effective component | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1986-08-20 | — | — | EP | disclosed |
| JP-S6092231-A | SYNTHETIC METHOD OF ACETAL | OSAKA SODA CO LTD | 1985-05-23 | — | — | JP | disclosed |
| JP-S6092233-A | NOVEL METHOD FOR SYNTHESIZING ALDEHYDE | OSAKA SODA CO LTD | 1985-05-23 | — | — | JP | disclosed |
| US-4503052-A | OXACEPHALOSPORIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1985-03-05 | — | — | US | disclosed |
| US-4338436-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4338439-A | BACTERICIDAL ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4319028-A | 7-(2-(Substituted benzoyl)amino)acetamido)cephalosporins | ELI LILLY AND COMPANY (US) | 1982-03-09 | — | — | US | disclosed |
| US-3954871-A | ANTIARRHYTHMIA, VASODILATOR, HYPOTENSIVE | CONTINENTAL PHARMA (BE) | 1976-05-04 | — | — | US | disclosed |
| US-3932498-A | ANTIINFLAMMATORY, ANTIPYRETICS, ANALGESICS | MERCK & CO., INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CA1 3083/4885CA2 1016/4885CA7 1625/4885 |
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | CA1 4647/4885CA2 2601/4885CA7 4661/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | CA1 140/4885CA2 458/4885CA7 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.